Evidence mapPaperPMID 25253227Full record

ArticleEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2014

American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease.

W Timothy Garvey, Alan J Garber, Jeffrey I Mechanick, George A Bray, Samuel Dagogo-Jack, Daniel Einhorn, George Grunberger, Yehuda Handelsman, Charles H Hennekens, Daniel L Hurley and 4 more

Registry-linked trialAbstract read
In one paragraph

Article in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03038620 (Impact of Liraglutide 3.0 on Body Fat Distribution, Visceral Adiposity, and Cardiometabolic Risk Markers In Overweight and Obese Adults at High Risk for Cardiovascular Disease), which is not on this map. Cited by 61 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 4 pooled it
23.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03038620 phase4completedstarted 2017, after this paper: background citation

Impact of Liraglutide 3.0 on Body Fat Distribution, Visceral Adiposity, and Cardiometabolic Risk Markers In Overweight and Obese Adults at High Risk for Cardiovascular Disease

Ran2017Enrolled235Registered outcomes37Posted comparisons0ConditionsCardiovascular Diseases, Fat Disorder, Obesity, VisceralArmsliraglutide, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 4 syntheses or guidelines pooled it, 232 citations in OpenAlex.

  1. Pooled it
  2. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. A Focus on the Pharmacotherapy of Obesity.Diabetes spectrum : a publication of the American Diabetes Association · 2024
    Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

W Timothy GarveyUAB Diabetes Research Center, GRECC Investigator and staff physician at the Birmingham VA Medical Center, Birmingham, AL.
Alan J GarberBiochemistry and Molecular Biology & Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX.
Jeffrey I MechanickDivision of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, NY.
George A BrayPennington Biomedical Research Center, Baton Rouge, LA.
Samuel Dagogo-JackUniversity of Tennessee, Memphis, TN.
Daniel EinhornDiabetes and Endocrine Associates, Scripps Whittier Diabetes Institute, University of California San Diego, LaJolla, CA.
George GrunbergerGrunberger Diabetes Institute; Internal Medicine and Molecular Medicine & Genetics, Wayne State University School of Medicine, Bloomfield Hills, MI.
Yehuda HandelsmanMetabolic Institute of America, Tarzana, CA.
Charles H HennekensFlorida Atlantic University, Boca Raton, FL.
Daniel L HurleyMayo Clinic Medical School, Rochester, MN.
Janet McGillDivision of Endocrinology, Metabolism & Lipid Research, Washington University, St. Louis, MO.
Pasquale PalumboMayo Clinic, Scottsdale, AZ.
Guillermo UmpierrezEmory University Department of Medicine/Endocrinology, Atlanta, GA.
The Aace Obesity Scientific Committee
Mayo Clinic in Arizona · USFlorida Atlantic University · USGrunberger Diabetes Institute · USIcahn School of Medicine at Mount Sinai · USPennington Biomedical Research Center · USTarzana Treatment Centers · USUniversity of Alabama at Birmingham · USUniversity of Tennessee Health Science Center · US

Funding

WU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · 2022 to 2025
$5.6M
UAB Diabetes Research CenterP30DK079626 · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2025 to 2025
$1.3M
CSRD VA I01 CX000432NIDDK NIH HHS P30 DK020579NIDDK NIH HHS P30 DK079626
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID25253227
PMCPMC4962331
OpenAlexW2148224299

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.